Among 5 analysts covering Home Capital Group Inc. (TSE:HCG), 1 have Buy rating, 0 Sell and 4 Hold. Therefore 20% are positive. Home Capital Group Inc. had 37 analyst reports since July 28, 2015 according to SRatingsIntel. RBC Capital Markets downgraded it to “Underperform” rating and $28 target in Monday, January 9 report. Raymond James maintained the stock with “Outperform” rating in Friday, February 10 report. The firm has “Sector Perform” rating by RBC Capital Markets given on Thursday, June 15. The company was maintained on Tuesday, December 8 by RBC Capital Markets. The firm has “Outperform” rating by Raymond James given on Friday, October 28. The firm earned “Underperform” rating on Thursday, November 5 by RBC Capital Markets. The rating was downgraded by RBC Capital Markets to “Sector Perform” on Friday, August 25. TD Securities upgraded it to “Buy” rating and $33 target in Friday, January 22 report. The firm has “Sector Outperform” rating by Scotia Capital given on Friday, July 31. The stock has “Sector Perform” rating by Scotia Capital on Thursday, November 3. See Home Capital Group Inc. (TSE:HCG) latest ratings:
The stock of Endologix, Inc. (NASDAQ:ELGX) is a huge mover today! The stock increased 4.43% or $0.18 during the last trading session, reaching $4.24. About 327,089 shares traded. Endologix, Inc. (NASDAQ:ELGX) has declined 63.00% since March 16, 2017 and is downtrending. It has underperformed by 79.70% the S&P500.The move comes after 8 months positive chart setup for the $354.65 million company. It was reported on Mar, 16 by Barchart.com. We have $4.54 PT which if reached, will make NASDAQ:ELGX worth $24.83 million more.
The stock decreased 0.40% or $0.06 during the last trading session, reaching $14.96. About 32,972 shares traded. Home Capital Group Inc. (TSE:HCG) has 0.00% since March 16, 2017 and is . It has underperformed by 16.70% the S&P500.
Home Capital Group Inc., through its subsidiary, Home Trust Company, provides deposits, mortgage lending, retail credit, and credit card issuing services in Canada. The company has market cap of $1.20 billion. It offers various deposit products, such as savings account demand products; and single-family residential and insured residential lending, as well as residential and non-residential commercial mortgage lending services. It has a 149.6 P/E ratio. The firm also provides credit card lending services, including Equityline Visa product that is secured by residential property; and cash-secured Visa products and unsecured Visa cards.
Among 10 analysts covering Endologix Inc. (NASDAQ:ELGX), 3 have Buy rating, 1 Sell and 6 Hold. Therefore 30% are positive. Endologix Inc. has $20 highest and $4.0 lowest target. $7.50’s average target is 76.89% above currents $4.24 stock price. Endologix Inc. had 45 analyst reports since August 4, 2015 according to SRatingsIntel. The firm has “Hold” rating by Canaccord Genuity given on Thursday, August 17. The stock has “Hold” rating by BMO Capital Markets on Wednesday, October 11. The firm earned “Buy” rating on Monday, September 28 by BTIG Research. The firm earned “Hold” rating on Friday, September 8 by BMO Capital Markets. The stock of Endologix, Inc. (NASDAQ:ELGX) has “Hold” rating given on Friday, October 6 by Stifel Nicolaus. The firm earned “Hold” rating on Wednesday, November 8 by RBC Capital Markets. RBC Capital Markets maintained it with “Outperform” rating and $15 target in Tuesday, November 17 report. BMO Capital Markets maintained the stock with “Hold” rating in Monday, June 19 report. The stock of Endologix, Inc. (NASDAQ:ELGX) earned “Hold” rating by Stifel Nicolaus on Thursday, May 18. Stifel Nicolaus maintained the stock with “Hold” rating in Wednesday, August 2 report.
Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company has market cap of $354.65 million. It offers minimally-invasive endovascular repair products, including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the ovation abdominal stent graft system. It currently has negative earnings. The firm also provides endovascular sealing (EVAS) product that is based on the Nellix EVAS system to seal the aneurysm, and provides blood flow to the legs through two blood lumens.